After the tumultuous year that 2020 was,
we invited responses for our “COVID-19
and Compliance Teams in Life
Sciences Industry” survey to gauge
the impact of the COVID pandemic on
compliance departments across life
sciences companies.
The survey was divided to record
responses with respect to compliance
teams size, budgets, use of counsel,
mode of monitoring and training.
In this survey 83.3% of the respondents
were Compliance professionals from
Pharmaceutical/Drug manufacturers,
and 16.7% from Medical Device
manufacturers. Out of those, 58.3%
belonged to a company with less than $1
billion annual revenue and 41.7%
belonged to a company that generated
between $1 billion to $10 billion annual
revenue.
To download, simply log in or register for an Informa Connect account below, which will give you access to all our exclusive premium content.
Log in or Create an Informa Connect Account to Access this content
Creating an account also means you'll get special access to article updates and exclusive industry content.